Figure 4 Quality-of-life analysis
(A) Percent change in dexamethasone from baseline in bevacizumab (Bev)–treated group (top) and control group (bottom) from the start of treatment to 1 month after failure. (B) Time to dexamethasone increase in control vs bevacizumab-treated group. (C) Time to decrease in Karnofsky Performance Status between control vs bevacizumab-treated group.